Astria Therapeutics' (ATXS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS - Free Report) in a report issued on Friday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the biotechnology company's stock.

A number of other equities analysts have also issued reports on ATXS. Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Stock Up 2.1%

Astria Therapeutics stock traded up $0.12 during midday trading on Friday, reaching $5.72. The company's stock had a trading volume of 346,240 shares, compared to its average volume of 372,556. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92. The company has a market cap of $322.80 million, a P/E ratio of -2.74 and a beta of 0.39. The business has a 50-day simple moving average of $4.61 and a 200-day simple moving average of $6.59.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). As a group, equities analysts forecast that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its position in Astria Therapeutics by 317.3% in the first quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company's stock valued at $582,000 after purchasing an additional 82,805 shares during the period. ADAR1 Capital Management LLC lifted its position in Astria Therapeutics by 605.3% in the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after purchasing an additional 550,706 shares during the period. PDT Partners LLC lifted its position in Astria Therapeutics by 173.2% in the first quarter. PDT Partners LLC now owns 28,707 shares of the biotechnology company's stock valued at $153,000 after purchasing an additional 18,200 shares during the period. Cubist Systematic Strategies LLC lifted its position in Astria Therapeutics by 503.7% in the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company's stock valued at $493,000 after purchasing an additional 76,961 shares during the period. Finally, DAFNA Capital Management LLC lifted its position in Astria Therapeutics by 5.0% in the first quarter. DAFNA Capital Management LLC now owns 314,775 shares of the biotechnology company's stock valued at $1,681,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.